+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID03604835

Global Long-Term Monitoring Program for Mucopolysaccharidosis VII Disease to Assess Clinical Progression and Treatment with Vestronidase Alfa

Led by Ultragenyx Pharmaceutical Inc · Updated on 2026-08-27

50

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The Mucopolysaccharidosis VII Disease Monitoring Program MPS VII DMP is a global, prospective, and longitudinal study aimed at understanding the presentation and progression of MPS VII disease. It evaluates the long-term effectiveness and safety of vestronidase alfa, focusing on hypersensitivity reactions and immunogenicity. This program includes both treated and untreated patients to provide comprehensive real-world data. Participants are observed over time through this non-randomized study. Some patients receive vestronidase alfa through prescription or early access programs, while others receive no treatment or treatments other than vestronidase alfa. The study collects standardized clinical data from multiple sites worldwide to capture disease heterogeneity and progression. During the study, participants undergo clinical assessments and provide patient- or caregiver-reported information at scheduled visits. Researchers monitor biomarkers, track the disease course, and evaluate the long-term safety and effectiveness of the treatment over a period of up to ten years. The study aims to generate high-quality data to better understand MPS VII and its management.

CONDITIONS

Brief Title

Mucopolysaccharidosis VII Disease Monitoring Program

Research Team

P

Patients Contact: Trial Recruitment

H

HCPs Contact: Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here